

REFERENCES

1. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Society.:: *Eur Respir J* 1998; 11:986–991.
2. Grimshaw J., Eccles M., Russell I. : Developing clinically valid practice guidelines.:: *J Eval Clin Pract* 1995; 1:37–48.
3. Guyatt G., Schunemann H., Cook D., Jaeschke R., Pauker S., Bucher H. : Grades of recommendation for antithrombotic agents.:: *Chest* 2001; 119(1 Suppl):3S–7S.
4. Harbour R., Miller J. : A new system for grading recommendations in evidence based guidelines.:: *BMJ* 2001; 323:334–336.
5. Guyatt GH., Sackett DL., Sinclair JC., Hayward R., Cook DJ., Cook RJ. : Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group.:: *JAMA* 1995; 274:1800–1804.
6. Hueston WJ., Mainous AG III., Dacus EN., Hopper JE. : Does acute bronchitis really exist? A reconceptualization of acute viral respiratory infections.:: *J Fam Pract* 2000; 49:401–406.
7. Metlay JP., Kapoor WN., Fine MJ. : Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.:: *JAMA* 1997; 278:1440–1445.
8. Wipf JE., Lipsky BA., Hirschmann JV., Boyko EJ., Takasugi J., Peugeot RL., *et al.* : Diagnosing pneumonia by physical examination: relevant or relic?:: *Arch Intern Med* 1999; 159:1082–1087.
9. Hope-Simpson RE., Miller DL. : The definition of acute respiratory illnesses in general practice.:: *Postgrad Med J* 1973; 49:763–770.
10. Coenen S., Van Royen P., Vermeire E., Hermann I., Denekens J. : Antibiotics for coughing in general practice: a qualitative decision analysis.:: *Fam Pract* 2000; 17:380–385.
11. Howie JG., Richardson IM., Gill G., Durno D. : Respiratory illness and antibiotic use in general practice.:: *J R Coll Gen Pract* 1971; 21:657–663.
12. Verheij TJ., Hermans J., Kaptein AA., Wijkkel D., Mulder JD. : Acute bronchitis: general practitioners' views regarding diagnosis and treatment.:: *Fam Pract* 1990; 7:175–180.
13. Stocks N., Fahey T. : Labelling of acute respiratory illness: evidence of between-practitioner variation in the UK.:: *Fam Pract* 2002; 19:375–377.
14. Macfarlane J., Holmes W., Gard P., Macfarlane R., Rose D., Weston V., *et al.* : Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community.:: *Thorax* 2001; 56:109–114.

15. Boldy DA., Skidmore SJ., Ayres JG. : Acute bronchitis in the community: clinical features, infective factors, changes in pulmonary function and bronchial reactivity to histamine.:: *Respir Med* 1990; 84:377–385.
16. Gonzales R., Barrett PH Jr., Crane LA., Steiner JF.: Factors associated with antibiotic use for acute bronchitis.:: *J Gen Intern Med* 1998; 13:541–548.
17. Thiadens HA., Postma DS., de Bock GH., Huysman DA., van Houwelingen HC., Springer MP. : Asthma in adult patients presenting with symptoms of acute bronchitis in general practice.:: *Scand J Prim Health Care* 2000; 18:188–192.
18. Oeffinger KC., Snell LM., Foster BM., Panico KG., Archer RK. : Diagnosis of acute bronchitis in adults: a national survey of family physicians.:: *J Fam Pract* 1997; 45:402–409.
19. Bent S., Saint S., Vittinghoff E., Grady D. : Antibiotics in acute bronchitis: a meta-analysis.:: *Am J Med* 1999; 107:62–67.
20. Verheij T., Hermans J., Kaptein A., Mulder J. : Acute bronchitis: course of symptoms and restrictions in patients' daily activities.:: *Scand J Prim Health Care* 1995; 13:8–12.
21. Thiadens HA., de Bock GH., Van Houwelingen JC., Dekker FW., De Waal MW., Springer MP., *et al.* : Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV(1) in primary care patients presenting with a persistent cough?: *Thorax* 1999; 54:1055–1060.
22. Fahey T., Stocks N., Thomas T. : Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults.:: *BMJ* 1998; 316:906–910.
23. Williamson HA Jr., Schultz P.: An association between acute bronchitis and asthma.:: *J Fam Pract* 1987; 24:35–38.
24. Melbye H., Kongerud J., Vorland L. : Reversible airflow limitation in adults with respiratory infection.:: *Eur Respir J* 1994; 7:1239–1245.
25. Jonsson JS., Gislason T., Gislason D., Sigurdsson JA. : Acute bronchitis and clinical outcome three years later: prospective cohort study.:: *BMJ* 1998; 317:1433.
26. Hallett JS., Jacobs RL. : Recurrent acute bronchitis: the association with undiagnosed bronchial asthma.:: *Ann Allergy* 1985; 55:568–570.
27. Macfarlane JT., Colville A., Guion A., Macfarlane RM., Rose DH. : Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community.:: *Lancet* 1993; 341:511–514.
28. Fleming DM., Ayres JG. : Diagnosis and patterns of incidence of influenza, influenza-like illness and the common cold in general practice.:: *J R Coll Gen Pract* 1988; 38:159–162.

29. Hayden FG., Osterhaus AD., Treanor JJ., Fleming DM., Aoki FY., Nicholson KG., *et al.* : Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group.: N Engl J Med 1997; 337:874–880.
30. Makela MJ., Pauksens K., Rostila T., Fleming DM., Man CY., Keene ON., *et al.* : Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.: J Infect 2000; 40:42–48.
31. Matsumoto K., Ogawa N., Nerome K., Numazaki Y., Kawakami Y., Shirato K., *et al.* : Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.: Antivir Ther 1999; 4:61–68.
32. Monto AS., Fleming DM., Henry D., de Groot R., Makela M., Klein T., *et al.* : Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections.: J Infect Dis 1999; 180:254–261.
33. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.: Lancet 1998; 352:1877–1881.
34. Nicholson KG., Aoki FY., Osterhaus AD., Trottier S., Carewicz O., Mercier CH., *et al.* : Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.: Lancet 2000; 355:1845–1850.
35. Treanor JJ., Hayden FG., Vrooman PS., Barbarash R., Bettis R., Riff D., *et al.* : Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.: JAMA 2000; 283:1016–1024.
36. van Elden LJ., van Essen GA., Boucher CA., Van Loon AM., Nijhuis M., Schipper P., *et al.* : Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice.: Br J Gen Pract 2001; 51:630–634.
37. Monto AS., Gravenstein S., Elliott M., Colopy M., Schweinle J. : Clinical signs and symptoms predicting influenza infection.: Arch Intern Med 2000; 160:3243–3247.
38. Zambon M., Hays J., Webster A., Newman R., Keene O. : Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza.: Arch Intern Med 2001; 161:2116–2122.
39. Zambon MC., Stockton JD., Clewley JP., Fleming DM. : Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study.: Lancet 2001; 358:1410–1416.
40. Walsh EE., Cox C., Falsey AR. : Clinical features of influenza A virus infection in older hospitalized persons.: J Am Geriatr Soc 2002; 50:1498–1503.

41. Heckerling PS. : The need for chest roentgenograms in adults with acute respiratory illness. Clinical predictors.:: Arch Intern Med 1986; 146:1321–1324.
42. Woodhead MA., Macfarlane JT., McCracken JS., Rose DH., Finch RG. : Prospective study of the aetiology and outcome of pneumonia in the community.:: Lancet 1987; 1:671–674.
43. Melbye H., Straume B., Aasebo U., Brox J. : The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests: Scand J Prim Health Care 1988; 6:111–117.
44. Melbye H., Straume B., Aasebo U., Dale K. : Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard.: Scand J Prim Health Care 1992; 10:226–233.
45. Melbye H., Berdal BP., Straume B., Russell H., Vorland L., Thacker WL. : Pneumonia--a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice: Scand J Infect Dis 1992; 24:647–655.
46. Christensen-Szalanski JJ., Bushyhead JB. : Physicians' misunderstanding of normal findings: Med Decis Making 1983; 3:169–175.
47. Melbye H., Straume B., Aasebo U., Brox J. : The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests: Scand J Prim Health Care 1988; 6:111–117.
48. Gennis P., Gallagher J., Falvo C., Baker S., Than W. : Clinical criteria for the detection of pneumonia in adults: guidelines for ordering chest roentgenograms in the emergency department: J Emerg Med 1989; 7:263–268.
49. Shaw AB., Fry J. : Acute infections of the chest in general practice: Br Med J 1955; ii:1577–1586.
50. Everett MT. : Major chest infection managed at home: Practitioner 1983; 227:1743–1754.
51. Woodhead MA. : Studies on pneumonia in the community and in hospital in Nottingham. University of Nottingham, 1988.
52. Diehr P., Wood RW., Bushyhead J., Krueger L., Wolcott B., Tompkins RK. : Prediction of pneumonia in outpatients with acute cough--a statistical approach: J Chronic Dis 1984; 37:215–225.
53. Heckerling PS., Conant RC., Tape TG., Wigton RS. : Reproducibility of predictor variables from a validated clinical rule: Med Decis Making 1992; 12:280–285.
54. Heckerling PS., Tape TG., Wigton RS., Hissong KK., Leikin JB., Ornato JP., *et al.* : Clinical prediction rule for pulmonary infiltrates: Ann Intern Med 1990; 113:664–670.

55. Mehr DR., Binder EF., Kruse RL., Zweig SC., Madsen RW., D'Agostino RB. : Clinical findings associated with radiographic pneumonia in nursing home residents: *J Fam Pract* 2001; 50:931–937.
56. Tape TG., Heckerling PS., Ornato JP., Wigton RS. : Use of clinical judgment analysis to explain regional variations in physicians' accuracies in diagnosing pneumonia: *Med Decis Making* 1991; 11:189–197.
57. Melbye H., Straume B. : The spectrum of patients strongly influences the usefulness of diagnostic tests for pneumonia: *Scand J Prim Health Care* 1993; 11:241–246.
58. Emerman CL., Dawson N., Speroff T., Siciliano C., Effron D., Rashad F., *et al.* : Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients: *Ann Emerg Med* 1991; 20:1215–1219.
59. Heckerling PS., Tape TG., Wigton RS. : Relation of physicians' predicted probabilities of pneumonia to their utilities for ordering chest x-rays to detect pneumonia: *Med Decis Making* 1992; 12:32–38.
60. Christensen-Szalanski JJ., Diehr PH., Bushyhead JB., Wood RW. : Two studies of good clinical judgment: *Med Decis Making* 1982; 2:275–283.
61. Young M., Marrie TJ. : Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia.: *Arch Intern Med* 1994; 154:2729–2732.
62. Melbye H., Dale K. : Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia: *Acta Radiol* 1992; 33:79–81.
63. Syrjala H., Broas M., Suramo I., Ojala A., Lahde S. : High-resolution computed tomography for the diagnosis of community-acquired pneumonia: *Clin Infect Dis* 1998; 27:358–363.
64. Pauwels RA., Buist AS., Calverley PM., Jenkins CR., Hurd SS. : Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary: *Am J Respir Crit Care Med* 2001; 163:1256–1276.
65. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS: *Thorax* 1997; 52 Suppl 5:S1–28.
66. Rodriguez-Roisin R. : Toward a consensus definition for COPD exacerbations.: *Chest* 2000; 117(5 Suppl 2):398S–401S.
67. Anthonisen NR., Manfreda J., Warren CP., Hershfield ES., Harding GK., Nelson NA. : Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease: *Ann Intern Med* 1987; 106:196–204.

68. Seemungal TA., Donaldson GC., Paul EA., Bestall JC., Jeffries DJ., Wedzicha JA. : Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease: *Am J Respir Crit Care Med* 1998; 157(5 Pt 1):1418–1422.
69. Ball P., Harris JM., Lowson D., Tillotson G., Wilson R. : Acute infective exacerbations of chronic bronchitis.: *QJM* 1995; 88:61–68.
70. Tsang KW., Chan WM., Ho PL., Chan K., Lam WK., Ip MS. : A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis.: *Eur Respir J* 1999; 14:1206–1209.
71. Silverman PM., Godwin JD. : CT/bronchographic correlations in bronchiectasis: *J Comput Assist Tomogr* 1987; 11:52–56.
72. Cooke JC., Currie DC., Morgan AD., Kerr IH., Delany D., Strickland B., *et al.* : Role of computed tomography in diagnosis of bronchiectasis.: *Thorax* 1987; 42:272–277.
73. O'Brien C., Guest PJ., Hill SL., Stockley RA. : Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care: *Thorax* 2000; 55:635–642.
74. Jokinen C., Heiskanen L., Juvonen H., Kallinen S., Karkola K., Korppi M., *et al.* : Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland.: *Am J Epidemiol* 1993; 137:977–988.
75. Almirall J., B.olibar I., Vidal J., Sauca G., Coll P., Niklasson B., *et al.* : Epidemiology of community-acquired pneumonia in adults: a population-based study.: *Eur Respir J* 2000; 15:757–763.
76. Marston BJ., Plouffe JF., File TM Jr., Hackman BA., Salstrom SJ., Lipman HB., *et al.*: Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group: *Arch Intern Med* 1997; 157:1709–1718.
77. Koivula I., Sten M., Leinonen M., Makela PH. : Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.: *Am J Med* 1997; 103:281–290.
78. Koivula I., Sten M., Makela PH. : Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study.: *Arch Intern Med* 1999; 159:1550–1555.
79. Jokinen C., Heiskanen L., Juvonen H., Kallinen S., Kleemola M., Koskela M., *et al.* : Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland.: *Clin Infect Dis* 2001; 32:1141–1154.
80. Monge V., Gonzalez A. : Hospital admissions for pneumonia in Spain.: *Infection* 2001; 29:3–6.

81. Fleming DM., Zambon M., Bartelds AI., de Jong JC. : The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands: *Eur J Epidemiol* 1999; 15:467–473.
82. Knottnerus JA. : Influenza in The Netherlands: *Pharmacoeconomics* 1996; 9 Suppl 3:46–49.
83. Simonsen L., Fukuda K., Schonberger LB., Cox NJ. : The impact of influenza epidemics on hospitalizations: *J Infect Dis* 2000; 181:831–837.
84. Lovering AM., MacGowan AP., Anderson P., Irwin D. : Epidemiology and resource utilization for patients hospitalized for lower respiratory tract infection.: *Clin Microbiol Infect* 2001; 7:666–670.
85. OPCS. Morbidity statistics from general practice. Fourth national study 1991–1992. 1995. London, HMSO.
86. Anderson H., Esmail A., Hollowell J., Littlejohns P., Strachan D. : Epidemiologically based needs assessment. Lower respiratory disease. NHS Management Executive. Report 16. 1993. NHS Management Executive.
87. Almirall J., Morato I., Riera F., Verdaguer A., P.riu R., Coll P., *et al.* : Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study.: *Eur Respir J* 1993; 6:14–18.
88. Schaberg T., Gialdroni-Grassi G., Huchon G., Leophonte P., Manresa F., Woodhead M. : An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections. The European Study Group of Community Acquired Pneumonia (ESOCAP) of the European Respiratory Society: *Thorax* 1996; 51:1017–1022.
89. Almirall J., Mesalles E., Klamburg J., Parra O., Agudo A. : Prognostic factors of pneumonia requiring admission to the intensive care unit.: *Chest* 1995; 107:511–516.
90. Garcia-Ordonez M.A., Garcia-Jimenez JM., Paez F., Alvarez F., Poyato B., Franquelo M., *et al.* : Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia.: *Eur J Clin Microbiol Infect Dis* 2001; 20:14–19.
91. Gowardman J., Trent L. : Severe community acquired pneumonia: a one-year analysis in a tertiary referral intensive care unit.: *N Z Med J* 2000; 113:161–164.
92. Laurichesse H., S.otto A., Bonnet E., Abraham B., Neau D., Badiaga S., *et al.* : Pre- and in-hospital management of community-acquired pneumonia in southern France, 1998–99.: *Eur J Clin Microbiol Infect Dis* 2001; 20:770–778.
93. Leroy O., Vandenbussche C., Coffinier C., Bosquet C., Georges H., Guery B., *et al.* : Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data: *Am J Respir Crit Care Med* 1997; 156:1922–1929.

94. Leroy O., Bosquet C., Vandebussche C., Coffinier C., Georges H., Guery B., *et al.* : Community-acquired pneumonia in the intensive care unit: epidemiological and prognosis data in older people.:: J Am Geriatr Soc 1999; 47:539–546.
95. Leroy O., Guilley J., Georges H., Choisy P., Guery B., Alfandari S., *et al.* : Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia.:: J Crit Care 1999; 14:12–19.
96. Markowitz JS., Pashko S., Gutterman EM., Linde-Zwirble WT., Newbold RIII. : Death rates among patients hospitalized with community-acquired pneumonia: a reexamination with data from three States: Am J Public Health 1996; 86(8 Pt 1):1152–1154.
97. Munson MA., Stanek RJ. : Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.:: Am J Med 1999; 107(1A):34S–43S.
98. Rello J., Rodriguez R., Jubert P., Alvarez B. : Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia: Clin Infect Dis 1996; 23:723–728.
99. Watanakunakorn C., Bailey TA. : Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. A detailed analysis of 108 cases: Arch Intern Med 1997; 157:1965–1971.
100. Carrat F., Valleron AJ. : Influenza mortality among the elderly in France, 1980–90: how many deaths may have been avoided through vaccination?: J Epidemiol Community Health 1995; 49:419–425.
101. Koivula I., Sten M., Makela PH. : Risk factors for pneumonia in the elderly: Am J Med 1994; 96:313–320.
102. Farr BM., Sloman AJ., Fisch MJ. : Predicting death in patients hospitalized for community-acquired pneumonia: Ann Intern Med 1991; 115:428–436.
103. Ewig S., Torres A., Angeles MM., Angrill J., Rano A., de Roux A., *et al.* : Factors associated with unknown aetiology in patients with community-acquired pneumonia.:: Eur Respir J 2002; 20:1254–1262.
104. Almirall J., Bolibar I., Vidal J., Sauca G., Coll P., Niklasson B., *et al.* : Epidemiology of community-acquired pneumonia in adults: a population-based study.:: Eur Respir J 2000; 15:757–763.
105. Anzueto A., Niederman MS., Tillotson GS. : Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg *b.i.d.* versus clarithromycin 500 mg *b.i.d.* Bronchitis Study Group.:: Clin Ther 1998; 20:885–900.
106. Blasi F., Cosentini R., Raccanelli R., Rinaldi A., Denti F., Loprete F., *et al.* : Emerging pathogens of community-acquired pneumonia: a two-year prospective study.:: J Chemother 1995; 7 Suppl 4:115–116.

107. Bohte R., van Furth R., van den Broek PJ. : Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.: *Thorax* 1995; 50:543–547.
108. Brandenburg JA., Marrie TJ., Coley CM., Singer DE., Obrosky DS., Kapoor WN., *et al.* : Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.: *J Gen Intern Med* 2000; 15:638–646.
109. El Solh AA., Sikka P., Ramadan F., Davies J. : Etiology of severe pneumonia in the very elderly.: *Am J Respir Crit Care Med* 2001; 163(3 Pt 1):645–651.
110. Ginesu F., Pirina P., Deiola G., Ostera S., Mele S., Fois AG. : Etiology and therapy of community-acquired pneumonia: *J Chemother* 1997; 9:285–292.
111. Gomez J., Banos V., Ruiz GJ., Soto MC., Munoz L., Nunez ML., *et al.* : Prospective study of epidemiology and prognostic factors in community-acquired pneumonia.: *Eur J Clin Microbiol Infect Dis* 1996; 15:556–560.
112. Hedlund J., Kalin M., Ortqvist A. : Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions.: *Scand J Infect Dis* 1997; 29:387–392.
113. Hirani NA., Macfarlane JT. : Impact of management guidelines on the outcome of severe community acquired pneumonia.: *Thorax* 1997; 52:17–21.
114. Jones RN., Croco MA., Kugler KC., Pfaller MA., Beach ML. : Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997):. *Diagn Microbiol Infect Dis* 2000; 37:115–125.
115. Logroscino CD., Penza O., Locicero S., Losito G., Nardini S., Bertoli L., *et al.* : Community-acquired pneumonia in adults: a multicentric observational AIPO study.: *Monaldi Arch Chest Dis* 1999; 54:11–17.
116. Lorente ML., Falguera M., Nogues A., Gonzalez AR., Merino MT., Caballero MR. : Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a prospective clinical study.: *Thorax* 2000; 55:133–137.
117. Lim WS., Macfarlane JT., Boswell TC., Harrison TG., Rose D., Leinonen M., *et al.* : Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.: *Thorax* 2001; 56:296–301.
118. Marrie TJ., Peeling RW., Fine MJ., Singer DE., Coley CM., Kapoor WN. : Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course.: *Am J Med* 1996; 101:508–515.
119. Meijer A., Dagnelie CF., de Jong JC., De Vries A., Bestebroer TM., Van Loon AM., *et al.* : Low prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae among patients with symptoms of respiratory tract infections in Dutch general practices.: *Eur J Epidemiol* 2000; 16:1099–1106.

120. Menendez R., Cordoba J., de La CP., Cremades MJ., Lopez-Hontagas JL., Salavert M., *et al.* : Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia.: *Am J Respir Crit Care Med* 1999; 159:1868–1873.
121. Michetti G., Pugliese C., Bamberg M., Ori BM., Villa R., Maggi L., *et al.* : Community-acquired pneumonia: is there difference in etiology between hospitalized and out-patients?: *Minerva Med* 1995; 86:341–351.
122. Olaechea PM., Quintana JM., Gallardo MS., Insausti J., Maravi E., Alvarez B. : A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission.: *Intensive Care Med* 1996; 22:1294–1300.
123. Ruiz M., Ewig S., Marcos MA., Martinez J.A., Arancibia F., Mensa J., *et al.* : Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity.: *Am J Respir Crit Care Med* 1999; 160:397–405.
124. Socan M., Marinic-Fiser N., Kraigher A., Kotnik A., Logar M. : Microbial aetiology of community-acquired pneumonia in hospitalised patients.: *Eur J Clin Microbiol Infect Dis* 1999; 18:777–782.
125. Sopena N., Sabria M., Pedro-Botet ML., Manterola J.M., Matas L., Dominguez J., *et al.* : Prospective study of community-acquired pneumonia of bacterial etiology in adults.: *Eur J Clin Microbiol Infect Dis* 1999; 18:852–858.
126. Steinhoff D., Lode H., Ruckdeschel G., Heidrich B., Rolfs A., Fehrenbach FJ., *et al.* : Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin.: *Clin Infect Dis* 1996; 22:958–964.
127. Eller J., Ede A., Schaberg T., Niederman MS., Mauch H., Lode H. : Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.: *Chest* 1998; 113:1542–1548.
128. Miravittles M., Espinosa C., Fernandez-Laso E., Martos JA., Maldonado JA., Gallego M. : Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD: *Chest* 1999; 116:40–46.
129. Lieberman D., Lieberman D., Gelfer Y., Varshavsky R., Dvoskin B., Leinonen M., *et al.* : Pneumonic vs nonpneumonic acute exacerbations of COPD.: *Chest* 2002; 122:1264–1270.
130. Buscho RO., Saxtan D., Shultz PS., Finch E., Mufson MA. : Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis: *J Infect Dis* 1978; 137:377–383.
131. Sethi S., Evans N., Grant BJ., Murphy TF. : New strains of bacteria and exacerbations of chronic obstructive pulmonary disease: *N Engl J Med* 2002; 347:465–471.

132. Angrill J., Agusti C., de Celis R., Rano A., Gonzalez J., Sole T., *et al.* : Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.:: *Thorax* 2002; 57:15–19.
133. Ho PL., Chan KN., Ip MS., Lam WK., Ho CS., Yuen KY., *et al.* : The effect of *Pseudomonas aeruginosa* infection on clinical parameters in steady-state bronchiectasis.:: *Chest* 1998; 114:1594–1598.
134. Ewig S., Ruiz M., Torres A., Marco F., Martinez JA., Sanchez M., *et al.* : Pneumonia acquired in the community through drug-resistant *Streptococcus pneumoniae*.:: *Am J Respir Crit Care Med* 1999; 159:1835–1842.
135. Felmingham D., Robbins MJ., Tesfaslasie Y., Harding I., Shrimpton S., Gruneberg RN. : Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995–1996 cold season: *J Antimicrob Chemother* 1998; 41:411–415.
136. Felmingham D., Gruneberg RN. : The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections: *J Antimicrob Chemother* 2000; 45:191–203.
137. Groom AV., Wolsey D.H., Naimi TS., Smith K., Johnson S., Boxrud D., *et al.* : Community-acquired methicillin-resistant *Staphylococcus aureus* in a rural American Indian community.:: *JAMA* 2001; 286:1201–1205.
138. Marco F., Bouza E., Garcia-de-Lomas J., Aguilar L. : *Streptococcus pneumoniae* in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. The Spanish Surveillance Group for Respiratory Pathogens: *J Antimicrob Chemother* 2000; 46:557–564.
139. Melo-Cristino J., Fernandes ML., Serrano N. : A multicentre study of the antimicrobial susceptibility of *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis* isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal. :: *Microb Drug Resist* 2001; 7:33–38.
140. Schito GC., Debbia EA., Marchese A. : The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.:: *J Antimicrob Chemother* 2000; 46 Suppl T1:3–9.
141. Pallares R., Gudiol F., Linares J., Ariza J., Rufi G., Murgui L., *et al.* : Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.:: *N Engl J Med* 1987; 317:18–22.
142. Pallares R., Linares J., Vadillo M., Cabellos C., Manresa F., Viladrich PF., *et al.* : Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.:: *N Engl J Med* 1995; 333:474–480.
143. Feikin DR., Schuchat A., Kolczak M., Barrett NL., Harrison LH., Lefkowitz L., *et al.* : Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997.:: *Am J Public Health* 2000; 90:223–229.

144. Moroney JF., Fiore AE., Harrison LH., Patterson JE., Farley MM., Jorgensen JH., *et al.* : Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.: *Clin Infect Dis* 2001; 33:797–805.
145. Ailani RK., Agastya G., Ailani RK., Mukunda BN., Shekar R. : Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia.: *Arch Intern Med* 1999; 159:266–270.
146. Farr BM., Woodhead MA., Macfarlane J.T., Bartlett CL., McCracken JS., Wadsworth J., *et al.* : Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community.: *Respir Med* 2000; 94:422–427.
147. Loeb M., McGeer A., McArthur M., Walter S., Simor AE. : Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities: *Arch Intern Med* 1999; 159:2058–2064.
148. Niederman MS., Fein AM. : Pneumonia in the elderly: *Clin Geriatr Med* 1986; 2:241–268.
149. Lim WS., Macfarlane JT. : A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia: *Eur Respir J* 2001; 18:362–368.
150. Marrie TJ. : Epidemiology of community-acquired pneumonia in the elderly: *Semin Respir Infect* 1990; 5:260–268.
151. Mehr D.R., Zweig SC., Kruse RL., Popejoy L., Horman D., Willis D., *et al.* : Mortality from lower respiratory infection in nursing home residents. A pilot prospective community-based study: *J Fam Pract* 1998; 47:298–304.
152. Menec VH., MacWilliam L., Aoki FY. : Hospitalizations and deaths due to respiratory illnesses during influenza seasons: a comparison of community residents, senior housing residents, and nursing home residents.: *J Gerontol A Biol Sci Med Sci* 2002; 57:M629–M635.
153. Wada H., Nakajoh K., Satoh-Nakagawa T., Suzuki T., Ohru T., Arai H., *et al.* : Risk factors of aspiration pneumonia in Alzheimer’s disease patients.: *Gerontology* 2001; 47:271–276.
154. Terpenning MS., Taylor GW., Lopatin DE., Kerr CK., Dominguez BL., Loesche WJ. : Aspiration pneumonia: dental and oral risk factors in an older veteran population: *J Am Geriatr Soc* 2001; 49:557–563.
155. Osterweil D., Norman D. : An outbreak of an influenza-like illness in a nursing home.: *J Am Geriatr Soc* 1990; 38:659–662.
156. Fine MJ., Singer DE., Hanusa BH., Lave JR., Kapoor WN. : Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database.: *Am J Med* 1993; 94:153–159.
157. Barker WH., Mullooly JP. : Underestimation of the role of pneumonia and influenza in causing excess mortality: *Am J Public Health* 1981; 71:643–645.

158. Lange P., Vestbo J., Nyboe J. : Risk factors for death and hospitalization from pneumonia. A prospective study of a general population: *Eur Respir J* 1995; 8:1694–1698.
159. Muder RR., Brennen C., Swenson DL., Wagener M. : Pneumonia in a long-term care facility. A prospective study of outcome: *Arch Intern Med* 1996; 156:2365–2370.
160. Lipsky BA., Boyko EJ., Inui TS., Koepsell TD. : Risk factors for acquiring pneumococcal infections: *Arch Intern Med* 1986; 146:2179–2185.
161. Gilbert K., Fine MJ. : Assessing prognosis and predicting patient outcomes in community-acquired pneumonia: *Semin Respir Infect* 1994; 9:140–152.
162. Venkatesan P., Gladman J., Macfarlane JT., Barer D., Berman P., Kinnear W., *et al.*: A hospital study of community acquired pneumonia in the elderly: *Thorax* 1990; 45:254–258.
163. Ebright JR., Rytel MW. : Bacterial pneumonia in the elderly: *J Am Geriatr Soc* 1980; 28:220–223.
164. Garb JL., Brown RB., Garb JR., Tuthill RW. : Differences in etiology of pneumonias in nursing home and community patients: *JAMA* 1978; 240:2169–2172.
165. Valenti WM., Trudell RG., Bentley DW. : Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged: *N Engl J Med* 1978; 298:1108–1111.
166. Palmer LB., Albulak K., Fields S., Filkin AM., Simon S., Smaldone GC. : Oral clearance and pathogenic oropharyngeal colonization in the elderly: *Am J Respir Crit Care Med* 2001; 164:464–468.
167. Marrie TJ., Durant H., Yates L. : Community-acquired pneumonia requiring hospitalization: 5-year prospective study.: *Rev Infect Dis* 1989; 11:586–599.
168. Fine MJ., Smith DN., Singer DE. : Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study: *Am J Med* 1990; 89:713–721.
169. Levy M., Dromer F., Brion N., Leturdu F., Carbon C. : Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations: *Chest* 1988; 93:43–48.
170. Ortqvist A., Hedlund J., Grillner L., Jalonon E., Kallings I., Leinonen M., *et al.* : Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization.: *Eur Respir J* 1990; 3:1105–1113.
171. Woodhead MA., Macfarlane JT., Rodgers FG., Laverick A., Pilkington R., Macrae AD. : Aetiology and outcome of severe community-acquired pneumonia: *J Infect* 1985; 10:204–210.

172. Pachon J., Prados MD., Capote F., Cuello JA., Garnacho J., Verano A. : Severe community-acquired pneumonia. Etiology, prognosis, and treatment: *Am Rev Respir Dis* 1990; 142:369–373.

173. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service.: *Respir Med* 1992; 86:7–13.

174. Dahmash NS., Chowdhury MN. : Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study.: *Thorax* 1994; 49:71–76.

175. Moine P., Vercken JB., Chevret S., Chastang C., Gajdos P. : Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit.: *Chest* 1994; 105:1487–1495.

176. Fernandez-Sola J., Junque A., Estruch R., Monforte R., Torres A., Urbano-Marquez A. : High alcohol intake as a risk and prognostic factor for community-acquired pneumonia.: *Arch Intern Med* 1995; 155:1649–1654.

177. Ruiz M., Ewig S., Torres A., Arancibia F., Marco F., Mensa J., *et al.* : Severe community-acquired pneumonia. Risk factors and follow-up epidemiology: *Am J Respir Crit Care Med* 1999; 160:923–929.

178. Ortvist A., Grepe A., Julander I., Kalin M. : Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias.: *Scand J Infect Dis* 1988; 20:163–171.

179. Perlino CA., Rimland D. : Alcoholism, leukopenia, and pneumococcal sepsis.: *Am Rev Respir Dis* 1985; 132:757–760.

180. Torres A., Serra-Batlles J., Ferrer A., Jimenez P., Celis R., Cobo E., *et al.* : Severe community-acquired pneumonia. Epidemiology and prognostic factors.: *Am Rev Respir Dis* 1991; 144:312–318.

181. Sullivan RJ Jr., Dowdle WR., Marine WM., Hierholzer JC.: Adult pneumonia in a general hospital. Etiology and host risk factors: *Arch Intern Med* 1972; 129:935–942.

182. Dorff GJ., Rytel MW., Farmer SG., Scanlon G. : Etiologies and characteristic features of pneumonias in a municipal hospital. :: *Am J Med Sci* 1973; 266:349–358.

183. Moore MA., Merson MH., Charache P., Shepard RH. : The characteristics and mortality of outpatient-acquired pneumonia: *Johns Hopkins Med J* 1977; 140:9–14.

184. Davis GS., Winn WC Jr.: Legionnaires' disease: respiratory infections caused by *Legionella* bacteria: *Clin Chest Med* 1987; 8:419–439.

185. Falco V., Fernandez dS., Alegre J., Ferrer A., Martinez Vazquez JM.: *Legionella pneumophila*. A cause of severe community-acquired pneumonia: *Chest* 1991; 100:1007–1011.

186. Niederman MS. : Malnutrition and host lung defenses: implications for the pathogenesis and prevention of pneumonia. In: Ferranti R.D. RCFCAN, editor. Verona, Italy: Bi & Gi, 1992; pp. 87–98.
187. Baik I., Curhan GC., Rimm EB., Bendich A., Willett WC., Fawzi WW. : A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women: *Arch Intern Med* 2000; 160:3082–3088.
188. Brown KH., Gilman RH., Gaffar A., *et al.* : Infections associated with severe protein-calorie malnutrition in hospitalized infants and children.: *Nutr Res* 1981; 1:33–46.
189. Mullen JL., Gertner MH., Buzby GP., Goodhart GL., Rosato EF. : Implications of malnutrition in the surgical patient: *Arch Surg* 1979; 114:121–125.
190. Nwilo J., Freeman H., McCord C. : Malnutrition: an important determinant of fatal outcome in surgically treated pulmonary suppurative disease.: *J Natl Med Assoc* 1989; 81:525–529.
191. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service: *Q J Med* 1987; 62:195–220.
192. Kark JD., Lebiush M., Rannon L. : Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men.: *N Engl J Med* 1982; 307:1042–1046.
193. Almirall J., Gonzalez CA., Balanzo X., Bolibar I. : Proportion of community-acquired pneumonia cases attributable to tobacco smoking.: *Chest* 1999; 116:375–379.
194. Nuorti JP., Butler JC., Farley MM., Harrison LH., McGeer A., Kolczak MS., *et al.* : Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team: *N Engl J Med* 2000; 342:681–689.
195. Houston MS., Silverstein MD., Suman VJ. : Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Community-based study: *Arch Intern Med* 1997; 157:2190–2195.
196. Akbar DH. : Bacterial pneumonia: comparison between diabetics and non-diabetics.: *Acta Diabetol* 2001; 38:77–82.
197. Fang GD., Fine M., Orloff J., Arisumi D., Yu VL., Kapoor W., *et al.* : New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases: *Medicine (Baltimore)* 1990; 69:307–316.
198. Arancibia F., Bauer TT., Ewig S., Mensa J., Gonzalez J., Niederman MS., *et al.* : Community-acquired pneumonia due to gram-negative bacteria and *Pseudomonas aeruginosa*: incidence, risk, and prognosis.: *Arch Intern Med* 2002; 162:1849–1858.
199. Coggon D., Inskip H., Winter P., Pannett B. : Lobar pneumonia: an occupational disease in welders.: *Lancet* 1994; 344:41–43.

200. Austrian R., Douglas RM., Schiffman G., Coetzee AM., Koornhof HJ., Hayden-Smith S., *et al.* : Prevention of pneumococcal pneumonia by vaccination.:: *Trans Assoc Am Physicians* 1976; 89:184–194.
201. Benin AL., Benson RF., Arnold KE., Fiore AE., Cook PG., Williams LK., *et al.* : An outbreak of travel-associated Legionnaires disease and Pontiac fever: the need for enhanced surveillance of travel-associated legionellosis in the United States.:: *J Infect Dis* 2002; 185:237–243.
202. Benkel DH., McClure EM., Woolard D., Rullan JV., Miller GB Jr., Jenkins SR., *et al.*: Outbreak of Legionnaires' disease associated with a display whirlpool spa.:: *Int J Epidemiol* 2000; 29:1092–1098.
203. Brown J., Hort K., Bouwman R., Capon A., Bansal N., Goldthorpe I., *et al.* : Investigation and control of a cluster of cases of Legionnaires disease in western Sydney.:: *Commun Dis Intell* 2001; 25:63–66.
204. Jernigan DB., Hofmann J., Cetron MS., Genese CA., Nuorti JP., Fields BS., *et al.* : Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa.:: *Lancet* 1996; 347:494–499.
205. Keller DW., Hajjeh R., DeMaria A., Fields BS., Pruckler JM., Benson RS., *et al.* : Community outbreak of Legionnaires' disease: an investigation confirming the potential for cooling towers to transmit Legionella species.:: *Clin Infect Dis* 1996; 22:257–261.
206. Nava JM., Bella F., Garau J., Lite J., Morera MA., Marti C., *et al.* : Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.:: *Clin Infect Dis* 1994; 19:884–890.
207. Nuorti JP., Butler JC., Crutcher JM., Guevara R., Welch D., Holder P., *et al.* : An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.:: *N Engl J Med* 1998; 338:1861–1868.
208. Johanson WG., Pierce AK., Sanford JP. : Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli: *N Engl J Med* 1969; 281:1137–1140.
209. Ketai LH., Rypka G. : The course of nosocomial oropharyngeal colonization in patients recovering from acute respiratory failure.:: *Chest* 1993; 103:1837–1841.
210. Esposito AL. : Community-acquired bacteremic pneumococcal pneumonia. Effect of age on manifestations and outcome: *Arch Intern Med* 1984; 144:945–948.
211. Fransen H., Wolontis S. : Infections with viruses, Mycoplasma pneumoniae and bacteria in acute respiratory illness. A study of hospitalized patients, patients treated at home, and healthy subjects: *Scand J Infect Dis* 1969; 1:31–37.
212. Mardh PA., Hovelius B., Nordenfelt E., Rosenberg R., Soltesz LV. : The incidence and aetiology of respiratory tract infections in general practice--with emphasis on Mycoplasma pneumoniae.:: *Infection* 1976; 4(1 Suppl):40–48.

213. Berntsson E., Lagergard T., Strannegard O., Trollfors B. : Etiology of community-acquired pneumonia in out-patients.: *Eur J Clin Microbiol* 1986; 5:446–447.
214. Blanquer J., Blanquer R., Borrás R., Nauffal D., Morales P., Menendez R., *et al.* : Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.: *Thorax* 1991; 46:508–511.
215. Dulake CSJ. : The incidence of pneumonia in the UK - preliminary findings from Newcastle and London: *R Soc Med Int Congress and Symposium Series* 1989; 27:87–94.
216. Foy HM., Cooney MK., McMahan R., Grayston JT. : Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period.: *Am J Epidemiol* 1973; 97:93–102.
217. Aubertin J., Dabis F., Fleurette J., Bornstein N., Salamon R., Brottier E., *et al.* : Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France.: *Infection* 1987; 15:328–331.
218. Ausina V., Coll P., Sambeat M., Puig I., Condom MJ., Luquin M *et al.* : Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain.: *Eur J Clin Microbiol Infect Dis* 1988; 7:342–347.
219. Berntsson E., Blomberg J., Lagergard T., Trollfors B. : Etiology of community-acquired pneumonia in patients requiring hospitalization.: *Eur J Clin Microbiol* 1985; 4:268–272.
220. Burman LA., Trollfors B., Andersson B., Henrichsen J., Juto P., Kallings I., *et al.* : Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens.: *J Infect Dis* 1991; 163:1087–1093.
221. Holmberg H. : Aetiology of community-acquired pneumonia in hospital treated patients.: *Scand J Infect Dis* 1987; 19:491–501.
222. Hone R., Haugh C., O'Connor B., Hollingsworth J. : Legionella: an infrequent cause of adult community acquired pneumonia in Dublin.: *Ir J Med Sci* 1989; 158:230–232.
223. Macfarlane JT., Finch RG., Ward MJ., Macrae AD. : Hospital study of adult community-acquired pneumonia: *Lancet* 1982; 2:255–258.
224. McNabb WR., Shanson DC., Williams TD., Lant AF. : Adult community-acquired pneumonia in central London: *J R Soc Med* 1984; 77:550–555.
225. Ostergaard L., Andersen PL. : Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology: *Chest* 1993; 104:1400–1407.
226. Pareja A., Bernal C., Leyva A., Piedrola G., Maroto MC. : Etiologic study of patients with community-acquired pneumonia.: *Chest* 1992; 101:1207–1210.

227. Ruf B., Schurmann D., Horbach I., Fehrenbach FJ., Pohle HD. : The incidence of legionella pneumonia: a 1-year prospective study in a large community hospital.: Lung 1989; 167:11–22.
228. White RJ., Blainey AD., Harrison KJ., Clarke SK. : Causes of pneumonia presenting to a district general hospital.: Thorax 1981; 36:566–570.
229. Alkhayer M., Jenkins PF., Harrison BD. : The outcome of community acquired pneumonia treated on the intensive care unit.: Respir Med 1990; 84:13–16.
230. Leroy O., Santre C., Beuscart C., Georges H., Guery B., Jacquier JM., *et al.* : A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit.: Intensive Care Med 1995; 21:24–31.
231. Ortqvist A., Sterner G., Nilsson JA. : Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis: Scand J Infect Dis 1985; 17:377–386.
232. Rello J., Quintana E., Ausina V., Net A., Prats G. : A three-year study of severe community-acquired pneumonia with emphasis on outcome.: Chest 1993; 103:232–235.
233. Sorensen J., Forsberg P., Hakanson E., Maller R., Sederholm C., Soren L., *et al.*: A new diagnostic approach to the patient with severe pneumonia.: Scand J Infect Dis 1989; 21:33–41.
234. Beaty CD., Grayston JT., Wang SP., Kuo CC., Reto CS., Martin TR. : Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.: Am Rev Respir Dis 1991; 144:1408–1410.
235. CARILLI AD., GOHD RS., GORDON W. : A virologic study of chronic bronchitis.: N Engl J Med 1964; 270:123–127.
236. Eadie MB. : SEJGNER. Virologic studies in chronic bronchitis: Br Med J 1966; 2:671–673.
237. Fagon JY., Chastre J., Trouillet JL., Domart Y., Dombret M.C., Bornet M., *et al.* : Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients: Am Rev Respir Dis 1990; 142:1004–1008.
238. Gump DW., Phillips CA., Forsyth BR., McIntosh K., Lamborn KR., Stouch WH. : Role of infection in chronic bronchitis.: Am Rev Respir Dis 1976; 113:465–474.
239. Karnak D., Beng-sun S., Beder S., Kayacan O. : Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD): Respir Med 2001; 95:811–816.
240. Lamy ME., Pouthier-Simon F., Debacker-Willame E. : Respiratory viral infections in hospital patients with chronic bronchitis. Observations during periods of exacerbation and quiescence: Chest 1973; 63:336–341.

241. Lieberman D., Ben Yaakov M., Lazarovich Z., Ohana B., Boldur I. : Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: analysis of 250 hospitalizations.:: Eur J Clin Microbiol Infect Dis 2001; 20:698–704.
242. McNamara MJ., Phillips IA., Williams OB. : Viral and Mycoplasma pneumoniae infections in exacerbations of chronic lung disease.:: Am Rev Respir Dis 1969; 100:19–24.
243. Mogulkoc N., Karakurt S., Isalska B., Bayindir U., Celikel T., Korten V., *et al.* : Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.:: Am J Respir Crit Care Med 1999; 160:349–353.
244. Monso E., Ruiz J., Rosell A., Manterola J., Fiz J., Morera J., *et al.* : Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush: Am J Respir Crit Care Med 1995; 152(4 Pt 1):1316–1320.
245. Ross CA., McMichael S., Eadie MB., Lees AW., Murray EA., Pinkerton I. : Infective agents and chronic bronchitis.:: Thorax 1966; 21:461–464.
246. Seemungal T., Harper-Owen R., Bhowmik A., Moric I., Sanderson G., Message S., *et al.* : Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.:: Am J Respir Crit Care Med 2001; 164:1618–1623.
247. Soler N., Torres A., Ewig S., Gonzalez J., Celis R., El Ebiary M., *et al.* : Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.:: Am J Respir Crit Care Med 1998; 157(5 Pt 1):1498–1505.
248. Chan TH., Ho SS., Lai CK., Cheung SW., Chan RC., Cheng AF., *et al.* : Comparison of oral ciprofloxacin and amoxicillin in treating infective exacerbations of bronchiectasis in Hong Kong.:: Chemotherapy 1996; 42:150–156.
249. O'Donnell AE., Barker AF., Ilowite JS., Fick RB. : Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.:: Chest 1998; 113:1329–1334.
250. Felmingham D., Reinert RR., Hiraoka Y., Rodloff A. : Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative *in vitro* activity of the ketolide, telithromycin.:: J Antimicrob Chemother 2002; 50 Suppl S1:25–37.
251. Oteo J., Alos JL., Gomez-Garces JL. : Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study: J Antimicrob Chemother 2001; 47:215–218.
252. Roussel-Delvallez M., Chardon H., Dupont MJ., Fosse T., Fauchere JL., Laurans G., *et al.* : Change of pneumococcal resistance to antibiotics in adults between 1995 and 1997: a study in eight French counties.:: Int J Antimicrob Agents 2002; 19:389–396.

253. Vanhoof R., Carpentier M., Fagnart O., Garrino MG., Glupczynski Y., Gordts B., *et al.* : *In vitro* study on the antimicrobial activity of various antibiotics against clinical isolates of *Streptococcus pneumoniae* from Belgium collected during winter 1998–1999.:: *Acta Clin Belg* 2000; 55:312–322.
254. Maraki S., Christidou A., Tselentis Y. : Antimicrobial resistance and serotype distribution of *Streptococcus pneumoniae* isolates from Crete, Greece.:: *Int J Antimicrob Agents* 2001; 17:465–469.
255. Tarasi A., Venditti M., D’Ambrosio F., Pantosti A. : Antimicrobial susceptibility of invasive *Streptococcus pneumoniae* in Italy by agar dilution method and E test.:: *Microb Drug Resist* 1999; 5:215–218.
256. Reinert RR., Simic S., Al Lahham A., Reinert S., Lemperle M., Lutticken R. : Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study.:: *J Clin Microbiol* 2001; 39:1187–1189.
257. de Neeling AJ., Overbeek BP., Horrevorts AM., Ligtvoet EE., Goettsch WG. : Antibiotic use and resistance of *Streptococcus pneumoniae* in The Netherlands during the period 1994–1999.:: *J Antimicrob Chemother* 2001; 48:441–444.
258. Woodhead MA., Macfarlane JT. : Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias.:: *Br J Dis Chest* 1987; 81:133–139.
259. Ambrose PG., Grasela DM., Grasela TH., Passarell J., Mayer HB., Pierce PF. : Pharmacodynamics of fluoroquinolones against *Streptococcus pneumoniae* in patients with community-acquired respiratory tract infections.:: *Antimicrob Agents Chemother* 2001; 45:2793–2797.
260. Craig WA. : Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.:: *J Antimicrob Chemother* 1993; 31 Suppl D:149–158.
261. Craig WA. : Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins: *Diagn Microbiol Infect Dis* 1995; 22:89–96.
262. Craig WA. : Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.:: *Clin Infect Dis* 1998; 26:1–10.
263. Gotfried MH., Danziger LH., Rodvold KA. : Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects: *Chest* 2001; 119:1114–1122.
264. Ambrose PG., Grasela DM., Grasela TH., Passarell J., Mayer HB., Pierce PF. : Pharmacodynamics of fluoroquinolones against *Streptococcus pneumoniae* in patients with community-acquired respiratory tract infections.:: *Antimicrob Agents Chemother* 2001; 45:2793–2797.

265. Nightingale CH., Grant EM., Quintiliani R. : Pharmacodynamics and pharmacokinetics of levofloxacin.: *Chemotherapy* 2000; 46 Suppl 1:6–14.
266. Schentag JJ., Gilliland KK., Paladino JA. : What have we learned from pharmacokinetic and pharmacodynamic theories?: *Clin Infect Dis* 2001; 32 Suppl 1:S39–S46.
267. Moore RD., Lietman PS., Smith CR. : Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.: *J Infect Dis* 1987; 155:93–99.
268. Hyatt JM., McKinnon PS., Zimmer GS., Schentag JJ. : The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents: *Clin Pharmacokinet* 1995; 28:143–160.
269. MacGowan AP., Bowker KE. : Pharmacodynamics of antimicrobial agents and rationale for their dosing: *J Chemother* 1997; 9 Suppl 1:64–73.
270. Wildfeuer A., Ruhle KH., Bolcskei PL., Springsklee M. : Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patients.: *Infection* 1994; 22:149–151.
271. Sum ZM., Sefton AM., Jepson AP., Williams JD. : Comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin: *J Antimicrob Chemother* 1989; 23:861–868.
272. Ferslew KE., Daigneault EA., Aten EM., Roseman JM. : Pharmacokinetics and urinary excretion of clavulanic acid after oral administration of amoxicillin and potassium clavulanate: *J Clin Pharmacol* 1984; 24:452–456.
273. Petitpretz P., Chidiac C., Soriano F., Garau J., Stevenson K., Rouffiac E. : The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.: *Int J Antimicrob Agents* 2002; 20:119–129.
274. Molinaro M., Corona G., Fiorito V., Spreafico S., Bartoli AN., Zoia C. : Bioavailability of two different oral formulations of amoxicillin in healthy subjects.: *Arzneimittelforschung* 1997; 47:1406–1410.
275. Nathwani D., Wood MJ. Penicillins. : A current review of their clinical pharmacology and therapeutic use: *Drugs* 1993; 45:866–894.
276. Signs SA., Tan JS., Salstrom SJ., File TM. : Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration: *Antimicrob Agents Chemother* 1992; 36:1400–1403.
277. Drusano GL., Hutchison M. : The pharmacokinetics of meropenem.: *Scand J Infect Dis Suppl* 1995; 96:11–16.

278. Satterwhite JH., Cerimele BJ., Coleman DL., Hatcher BL., Kisicki J., DeSante KA. : Pharmacokinetics of cefaclor AF: effects of age, antacids and H₂-receptor Antagonists. *Postgrad Med J* 1992; 68 Suppl 3:S3–S9.
279. Donn KH., James NC., Powell JR. : Bioavailability of cefuroxime axetil formulations.:: *J Pharm Sci* 1994; 83:842–844.
280. Kees F., Naber KG., Sigl G., Ungethum W., Grobecker H. : Relative bioavailability of three cefixime formulations.:: *Arzneimittelforschung* 1990; 40:293–297.
281. Borin MT., Forbes KK., Hughes GS. : The bioavailability of cefpodoxime proxetil tablets relative to an oral solution: *Biopharm Drug Dispos* 1995; 16:295–302.
282. Lin CC., Affrime M., Radwanski E., Lim J., Colucci R., Cayen MN. : Comparative bioavailability of ceftibuten in capsule and suspension forms: *Clin Ther* 1996; 18:1139–1149.
283. Zimmerman J., Cohen A., Thyrum P. : Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.:: *J Clin Pharmacol* 1989; 29:151–157.
284. Borner K., Lode H., Hampel B., Pfeuffer M., Koeppel P. : Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration.:: *Chemotherapy* 1985; 31:237–245.
285. Delsignore R., Baroni CM., Crotti G., Mineo F., Butturini U., Ascalone V., *et al.* : Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers.:: *Chemotherapy* 1983; 29:157–162.
286. Barbhaiya RH., Knupp CA., Tenney J., Martin RR., Weidler DJ., Pittman KA. : Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects: *J Clin Pharmacol* 1990; 30:900–910.
287. Begg EJ., Robson RA., Saunders DA., Graham GG., Buttimore RC., Neill AM., *et al.* : The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.:: *Br J Clin Pharmacol* 2000; 49:32–38.
288. Chien SC., Rogge MC., Gisclon LG., Curtin C., Wong F., Natarajan J., *et al.* : Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.:: *Antimicrob Agents Chemother* 1997; 41:2256–2260.
289. Stass H., Kubitzka D. : Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.:: *J Antimicrob Chemother* 1999; 43 Suppl B:83–90.
290. Foulds G., Luke DR., Teng R., Willavize SA., Friedman H., Curatolo WJ. : The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension: *J Antimicrob Chemother* 1996; 37 Suppl C:37–44.

291. Chu SY., Deaton R., Cavanaugh J. : Absolute bioavailability of clarithromycin after oral administration in humans.: *Antimicrob Agents Chemother* 1992; 36:1147–1150.
292. Rutland J., Berend N., Marlin GE. : The influence of food on the bioavailability of new formulations of erythromycin stearate and base: *Br J Clin Pharmacol* 1979; 8:343–347.
293. Perret C., Lenfant B., Weinling E., Wessels DH., Scholtz HE., Montay G., *et al.* : Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers.: *Chemotherapy* 2002; 48:217–223.
294. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., *et al.* : *In vitro* activity and human pharmacokinetics of teicoplanin.: *Antimicrob Agents Chemother* 1984; 26:881–886.
295. Leader WG., Chandler MH., Castiglia M. : Pharmacokinetic optimisation of vancomycin therapy.: *Clin Pharmacokinet* 1995; 28:327–342.
296. Bauer LA., Edwards WA., Dellinger EP., Simonowitz DA. : Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients: *Eur J Clin Pharmacol* 1983; 24:643–647.
297. Regamey C., Gordon RC., Kirby WM. : Comparative pharmacokinetics of tobramycin and gentamicin.: *Clin Pharmacol Ther* 1973; 14:396–403.
298. Aarons L., Vozeh S., Wenk M., Weiss P., Follath F. : Population pharmacokinetics of tobramycin.: *Br J Clin Pharmacol* 1989; 28:305–314.
299. Saivin S., Houin G. : Clinical pharmacokinetics of doxycycline and minocycline.: *Clin Pharmacokinet* 1988; 15:355–366.
300. Garty M., Hurwitz A. : Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.: *Clin Pharmacol Ther* 1980; 28:203–207.
301. Mazur D., Schug BS., Evers G., Larsimont V., Fieger-Buschges H., Gimbel W., *et al.* : Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation.: *Int J Clin Pharmacol Ther* 1999; 37:386–392.
302. Gatti G., Flaherty J., Bulp J., White J., Borin M., Gambertoglio J. : Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.: *Antimicrob Agents Chemother* 1993; 37:1137–1143.
303. Meagher AK., Forrest A., Rayner CR., Birmingham MC., Schentag JJ. : Population pharmacokinetics of linezolid in patients treated in a compassionate-use program: *Antimicrob Agents Chemother* 2003; 47:548–553.
304. Paton DM., Webster DR. : Comparative bioavailability of two tablet preparations of metronidazole.: *Int J Clin Pharmacol Res* 1988; 8:227–229.

305. Lau AH., Lam NP., Piscitelli SC., Wilkes L., Danziger LH. : Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.: *Clin Pharmacokinet* 1992; 23:328–364.
306. Panchagnula R., Kaur KJ., Singh I., Kaul CL. : Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.: *Methods Find Exp Clin Pharmacol* 2000; 22:689–694.
307. Loos U., Musch E., Jensen JC., Mikus G., Schwabe HK., Eichelbaum M. : Pharmacokinetics of oral and intravenous rifampicin during chronic administration.: *Klin Wochenschr* 1985; 63:1205–1211.
308. Chevalier P., Rey J., Pasquier O., Rouzier-Panis R., Harding N., Montay G. : Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.: *J Clin Pharmacol* 2001; 41:404–414.
309. Nightingale CH., Grant EM., Quintiliani R. : Pharmacodynamics and pharmacokinetics of levofloxacin.: *Chemotherapy* 2000; 46 Suppl 1:6–14.
310. Schentag JJ., Gilliland KK., Paladino JA. : What have we learned from pharmacokinetic and pharmacodynamic theories?: *Clin Infect Dis* 2001; 32 Suppl 1:S39–S46.
311. Moore RD., Lietman PS., Smith CR. : Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.: *J Infect Dis* 1987; 155:93–99.
312. Hyatt JM., McKinnon PS., Zimmer GS., Schentag JJ. : The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents: *Clin Pharmacokinet* 1995; 28:143–160.
313. MacGowan AP., Bowker KE. : Pharmacodynamics of antimicrobial agents and rationale for their dosing: *J Chemother* 1997; 9 Suppl 1:64–73.
314. Olsen KM., San Pedro G., Gann LP., Gubbins PO., Halinski DM., Campbell GD Jr.: Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.: *Antimicrob Agents Chemother* 1996; 40:2582–2585.
315. Mazzei T., Novelli A., Esposito S., Periti P. : New insight into the clinical pharmacokinetics of cefaclor: tissue penetration.: *J Chemother* 2000; 12:53–62.
316. Benoni G., Arosio E., Cuzzolin L., Vaona B., Raimondi MG., Lechi A. : Penetration of ceftriaxone into human pleural fluid.: *Antimicrob Agents Chemother* 1986; 29:906–908.
317. Decre D., Bergogne-Berezin E. : Pharmacokinetics of quinolones with special reference to the respiratory tree.: *J Antimicrob Chemother* 1993; 31:331–343.
318. Patel KB., Xuan D., Tessier PR., Russomanno JH., Quintiliani R., Nightingale CH. : Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.: *Antimicrob Agents Chemother* 1996; 40:2375–2379.

319. Conte JE Jr., Golden JA., Duncan S., McKenna E., Zurlinden E.: Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.: *Antimicrob Agents Chemother* 1995; 39:334–338.
320. Benoni G., Cuzzolin L., Bertrand C., Puchetti V., Velo G. : Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy.: *J Antimicrob Chemother* 1987; 20:725–728.
321. Lee LJ., Sha X., Gotfried MH., Howard JR., Dix RK., Fish DN. : Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy.: *Pharmacotherapy* 1998; 18:35–41.
322. Conte JE Jr., Golden JA., Kipps J., Zurlinden E.: Intrapulmonary pharmacokinetics of linezolid.: *Antimicrob Agents Chemother* 2002; 46:1475–1480.
323. Bergogne-Berezin E., Muller-Serieys C., Aubier M., Dombret MC. : Concentration of meropenem in serum and in bronchial secretions in patients undergoing fiberoptic bronchoscopy.: *Eur J Clin Pharmacol* 1994; 46:87–88.
324. Simon N., Sampol E., Albanese J., Martin C., Arvis P., Urien S., *et al.* : Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.: *Clin Pharmacol Ther* 2003; 74:353–363.
325. Tomaselli F., Dittrich P., Maier A., Woltsche M., Matzi V., Pinter J., *et al.* : Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by *in vivo* microdialysis.: *Br J Clin Pharmacol* 2003; 55:620–624.
326. Muller-Serieys C., Soler P., Cantalloube C., Lemaitre F., Gia HP., Brunner F., *et al.* : Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647):. *Antimicrob Agents Chemother* 2001; 45:3104–3108.
327. Mazzei T., Novelli A., De Lalla F., Mini E., Periti P. : Tissue penetration and pulmonary disposition of tobramycin.: *J Chemother* 1995; 7:363–370.
328. Cruciani M., Gatti G., Lazzarini L., Furlan G., Broccali G., Malena M., *et al.* : Penetration of vancomycin into human lung tissue.: *J Antimicrob Chemother* 1996; 38:865–869.